Company Overview of Envisia Therapeutics Inc.
Envisia Therapeutics Inc. is engaged in the discovery and development of ocular therapeutics for the critical needs in ophthalmology. The company offers ENV515, a prostaglandin analogue that uses a biodegradable PRINT particle formulation to provide sustained intraocular pressure reduction over months. It also provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic, chemical, or other barriers that limit existing ocular therapies; therapeutics based on biocompatible polymers for the delivery of medicines with extended-release kinetics; and topical therapies for treating ocular diseases. The company was founded in 2013 and is based in Morrisville, North ...
419 Davis Drive
Morrisville, NC 27560
Founded in 2013
Key Executives for Envisia Therapeutics Inc.
Chief Executive Officer and Director
Co-Founder, President and Chief Scientific Officer
Compensation as of Fiscal Year 2016.
Envisia Therapeutics Inc. Key Developments
Envisia Therapeutics Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 04:30 PM
Jan 4 17
Envisia Therapeutics Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 04:30 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.
Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After a Single Dose in Patients With Glaucoma
Oct 17 16
Envisia Therapeutics Inc. released an interim analysis of its ENV515 (travoprost XR) phase 2 trial in glaucoma patients showing clinically meaningful reduction in intraocular pressure (IOP) for the entire nine-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops. The ongoing phase 2 trial is a 12-month safety and efficacy evaluation that enrolled five glaucoma patients at sites within the U.S. The pre-washout baseline for all patients in this cohort, treated with LUMIGAN or XALATAN prior to enrollment, was 19.7 mmHg, with a post-washout baseline of 26.1 mmHg for 8 AM IOP. Single low dose of ENV515 decreased the mean + SD 8 AM IOP by 6.7 ± 3.8 mmHg or 26% over nine months (mean of all 8 AM IOPs over nine months). The mean 8 AM IOP after a single low dose of ENV515 was 19.4 mmHg over the nine-month period. ENV515 was well tolerated and there were no serious adverse events, no changes in corneal endothelial cell counts evaluated by an independent reading center, and no changes in corneal thickness. The most common adverse event was early-onset transient hyperemia, or eye redness, related to the dosing procedure.
Envisia Therapeutics Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 09:00 AM
Sep 1 16
Envisia Therapeutics Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 09:00 AM. Venue: The Mandarin Oriental Hotel, Boston, Massachusetts, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 11, 2016